

Tavolixizumab (Synonyms: TAVOLIMAB [USAN]; Tavolimab [WHO-DD])



Catalog Number: 176802

Product name

Tavolixizumab (Synonyms: TAVOLIMAB [USAN]; Tavolimab [WHO-DD])

Specificity

Human TNFRSF4 / OX40 / CD134

Antibody description

Anti-TNFRSF4 / OX40 / CD134 Antibody (Tavolixizumab)

Preparation

Recombinant expression and purified from CHO cells.

Formulation

0.1 M Pro-Ac, 20 mM Arg, pH 5.0

Storage

-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

Clonality

Monoclonal


Ig Type

IgG1

Applications


ELISA

Validations




SDS-PAGE

Anti-TNFRSF4 / OX40 / CD134 Antibody (tavolixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



SEC-HPLC

The purity of Anti-TNFRSF4 / OX40 / CD134 Antibody (tavolixizumab) is 97.98%, determined



by SEC-HPLC.

Bioactivity: ELISA

Immobilized human CD134 His at 2 µg/mL can bind Anti-TNFRSF4 / OX40 / CD134 Antibody (tavolixizumab), EC50=0.03236 µg/mL.